OpenCRISPR-1: The First AI-Designed CRISPR Editor for High-Precision Gene & Cell Therapy
16 December 2025
Discover OpenCRISPR-1 — the first fully AI-designed CRISPR–Cas editor. Built by generative large language model, it enables high-efficiency, high-specificity genome and base editing in human cells. Ideal for cell therapy, stem-cell research, and advanced gene-editing workflows.
Key Challenges in Clinical iPSC Applications: How REPROCELL Helps You Succeed
12 May 2025
Overcome key challenges in clinical iPSC applications with REPROCELL's ethical sourcing, advanced reprogramming, and tailored solutions for reliable, scalable therapies.
The Therapeutic Advantage of Induced Pluripotent Stem Cells-Derived Mesenchymal Stem Cells (iMSCs)
24 February 2025
Discover the clinical benefits and advancements of using induced pluripotent stem cells-derived mesenchymal stem cells (iMSCs) in regenerative medicine and therapeutic applications.
Editing B2M and CIITA to Create Hypoimmune Cell Lines for Cell Therapy
29 August 2023
Gene editing is a viable approach for reducing immunogenicity of iPSC-derived therapeutic cells. The B2M and CIITA HLA-regulatory genes are good targets.
How digital droplet PCR can improve CRISPR gene editing (with examples)
05 October 2021
Looking to understand how digital PCR can improve your genome editing projects? Learn how digital PCR can improve your CRISPR gene editing (with examples).
What is digital droplet PCR and how can it improve stem cell therapies?
13 September 2021
Discover the definition of digital droplet PCR and how can it improve the safety of your stem cell therapies.
Three challenges facing the introduction of iPSC-derived therapies
12 February 2020
Discover three of the main challenges facing the introduction of iPSC-derived therapies on the REPROCELL blog.